BioCentury | Jun 17, 2013
Clinical News

Crolibulin: Phase I data

...in the open-label, dose-escalation Phase I portion of a U.S. Phase I/II trial showed that crolibulin...
...cisplatin was well tolerated up to the maximum tolerated dose (MTD) of 20 mg/m 2 crolibulin...
...Feb. 18, 2013). EpiCept Corp. (OTCQX:EPCT; SSE:EPCT), Tarrytown, N.Y. Product: Crolibulin ( EPC2407 ) (formerly crinobulin...
BioCentury | Jan 3, 2011
Clinical News

Crolibulin: Phase I/II started

...vs. cisplatin alone. EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT), Tarrytown, N.Y. Product: Crolibulin ( EPC2407 ) (formerly crinobulin...
BioCentury | Jun 8, 2009
Clinical News

Crinobulin: Phase Ia data

...Data from a Phase Ia trial in 11 patients showed that 13-30 mg/m 2 IV EPC2407...
...Both patients received 18 mg/m 2 IV EPC2407. The MTD was 24 mg/m 2 IV EPC2407...
...of Clinical Oncology meeting in Orlando. EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT), Tarrytown, N.Y. Product: Crinobulin ( EPC2407...
BioCentury | Jan 19, 2009
Company News

EpiCept cancer, neurology news

...for an NDA submission in 3Q09. The company will continue development of its pipeline including EPC2407...
BioCentury | Apr 14, 2008
Clinical News

EPC2407: Interim Phase I data

...In an ongoing open-label, U.S. Phase I trial, intravenous EPC2407 stabilized disease in 7 out of...
...in 7 out of 8 evaluable patients who received 4, 8 and 13 mg/kg of EPC2407...
...can be tolerated (see BioCentury, Oct. 15, 2007). EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT), Tarrytown, N.Y. Product: EPC2407...
BioCentury | Nov 12, 2007
Clinical News

EPC2407: Completed Phase Ia enrollment

...in an open-label, dose-escalation, U.S. Phase Ia trial. EpiCept Corp. (EPCT; SSE:EPCT), Tarrytown, N.Y. Product: EPC2407...
BioCentury | Nov 12, 2007
Clinical News

EPC2407: Phase Ib start

...patients to evaluate EPC2407 in combination with chemotherapy. EpiCept Corp. (EPCT; SSE:EPCT), Tarrytown, N.Y. Product: EPC2407...
BioCentury | Oct 29, 2007
Clinical News

EpiCept preclinical data

...In mouse models of NSCLC and breast cancer, EPC2407 significantly enhanced the activity of Avastin bevacizumab...
...marketed by Pfizer Inc. (PFE, New York, N.Y.). EpiCept Corp. (EPCT; SSE:EPCT), Tarrytown, N.Y. Product: EPC2407...
BioCentury | Oct 15, 2007
Clinical News

EPC2407: Phase I data

...and that the study met its pharmacokinetics endpoints. EpiCept Corp. (EPCT; SSE:EPCT), Tarrytown, N.Y. Product: EPC2407...
BioCentury | Mar 19, 2007
Clinical News

EPC2407: Phase I start

...In 2H07, EPCT will start a Phase I trial of EPC2407 as a combination therapy for...
...as a combination therapy for advanced solid tumors. EpiCept Corp. (EPCT; SSE:EPCT), Tarrytown, N.Y. Product: EPC2407...
Items per page:
1 - 10 of 12